

Step Therapy Criteria

ATYPICALS

Products Affected

Step 2:

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Criteria	Claim will pay automatically for Fanapt, Lybalvi or Vraylar if enrollee has a paid claim for at least a 1 day supply of Latuda or any 1 generic formulary atypical antipsychotic in the past 365 days. Otherwise, Fanapt, Lybalvi or Vraylar requires a step therapy exception request indicating: (1) history of inadequate treatment response with Latuda or any 1 generic formulary atypical antipsychotic, OR (2) history of adverse event with Latuda or any 1 generic formulary atypical antipsychotic, OR (3) Latuda or any 1 generic formulary atypical antipsychotic is contraindicated.
-----------------	---

RYTARY

Products Affected

Step 2:

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	Claim will pay automatically for Rytary if enrollee has a paid claim for at least a 1 day supply of any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone in the past 365 days. Otherwise, Rytary requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone OR (2) history of adverse event with any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone, OR (3) any generic carbidopa, carbidopa/levodopa, or carbidopa/levodopa/entacapone is contraindicated.
-----------------	--

Index

F

FANAPT TABLET 1 MG ORAL 1, 2
FANAPT TABLET 10 MG ORAL 1, 2
FANAPT TABLET 12 MG ORAL 1, 2
FANAPT TABLET 2 MG ORAL 1, 2
FANAPT TABLET 4 MG ORAL 1, 2
FANAPT TABLET 6 MG ORAL 1, 2
FANAPT TABLET 8 MG ORAL 1, 2
FANAPT TITRATION PACK TABLET 1
& 2 & 4 & 6 MG ORAL 1, 2

L

LYBALVI TABLET 10-10 MG ORAL . 1, 2
LYBALVI TABLET 15-10 MG ORAL . 1, 2
LYBALVI TABLET 20-10 MG ORAL . 1, 2
LYBALVI TABLET 5-10 MG ORAL ... 1, 2

R

RYTARY CAPSULE EXTENDED
RELEASE 23.75-95 MG ORAL.....3
RYTARY CAPSULE EXTENDED
RELEASE 36.25-145 MG ORAL.....3
RYTARY CAPSULE EXTENDED
RELEASE 48.75-195 MG ORAL.....3
RYTARY CAPSULE EXTENDED
RELEASE 61.25-245 MG ORAL.....3

V

VRAYLAR CAPSULE 1.5 MG ORAL.. 1, 2
VRAYLAR CAPSULE 3 MG ORAL..... 1, 2
VRAYLAR CAPSULE 4.5 MG ORAL.. 1, 2
VRAYLAR CAPSULE 6 MG ORAL..... 1, 2
VRAYLAR CAPSULE THERAPY PACK
1.5 & 3 MG ORAL..... 1, 2